在儿科中肠道微生物组的改变:对发作的影响和治疗方法
Teresa Ravizza1, Greta Volpedo2,3, Antonella Riva2,3
1Department of Acute Brain and Cardiovascular Injury, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
肠道微生物组影响大脑功能和. 患有的儿童的肠道细菌变化可能会使发作恶化,但针对肠道的治疗方法对发作控制有希望.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 儿科神经学 儿科神经学
背景情况:
- 肠道微生物群对宿主健康至关重要,影响胃肠道,免疫和中枢神经系统 (CNS) 功能.
- 肠道微生物群和大脑 (肠-大脑轴) 之间的双向通信越来越多地被认为在神经系统疾病 (包括) 中起作用.
- 肠道失生症,肠道微生物组成的改变,与儿科发作中的发作易感性有关.
研究的目的:
- 审查肠道微生物群在儿科中的作用,重点关注临床和临床前研究.
- 探索肠道微生物群改变对儿童控制和管理的影响.
- 讨论肠-大脑通信的潜在机制以及针对小儿的新型微生物组向治疗策略.
主要方法:
- 审查现有的临床和临床前研究,调查小儿的肠道微生物组.
- 对肠-大脑轴及其与神经功能联系的研究进行分析.
- 检查微生物组向疗法及其在临床前模型和临床环境中的疗效.
主要成果:
- 肠道功能失调与发作易感性增加有关,并且可以在临床前的模型中加剧发作.
- 针对微生物群的干预措施,包括性饮食,前/亲生素和便微生物群移植,显示出降低发作频率的潜力.
- 这些干预措施也显示出改善小儿中经常观察到的胃肠功能障碍的希望.
结论:
- 肠道微生物组及其相关功能在儿科中发生显著变化,特别是在耐药的情况下.
- 肠-大脑轴是治疗儿科的潜在治疗目标,为控制发作提供了新的途径.
- 准肠道微生物群作为一种新的战略,有望改善治疗结果,并减少患者儿童的抗药性发作.
更多相关视频
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
相关概念视频
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Anatomy of the Intestines
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
